Arca
Skip to content
Tools
Tools

Uveal melanoma

Drug research and approvals for uveal melanoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 42 studies of uveal melanoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, FDA has 2 approved and 10 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 42
  • Trials authorized in Canada: 10
  • FDA orphan approvals: 2
  • EU medicines: 1

Recruiting now

Newest posted first, of 42 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 9

Phase 2 12 of 49

Phase 1 or earlier 12 of 14

Trials authorized in Canada

Newest first; search them all in Canada trials
Jul 13, 2026A randomized, phase 3, open-label study of adjuvant darovasertib and crizotinib in participants with primary non-metastatic uveal melanoma (optimum-11)Darovasertib / CrizotinibIdeaya BiosciencesPending
Aug 28, 2025A randomized, phase 3, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (optimum-10)Darovasertib (IDE196)Ideaya BiosciencesOngoing
Jan 23, 2025A randomized clinical trial evaluating intravitreal faricimab (6.0 mg) injections of fluocinolone acetonide (0.19 mg) intravitreal implants vs. observation for…Faricimab / FluocinoloneJaeb Center for Health Research Foundation, IncPending
Oct 6, 2023Ide196 (darovasertib) in combination with crizotinib versus investigator's choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal…Darovasertib (IDE196) / CrizotinibIdeaya BiosciencesOngoing
Aug 30, 2023(NEO)adjuvant IDE196 (darovasertib) in patients with localized ocular melanomaDarovasertib (IDE196) / Metformin / Norethindrone-ethinyl estradiolIdeaya BiosciencesOngoing
Aug 12, 2021A phase 1/2 study of IDE196 in patients with solid tumors harboring gnaq/11 mutations or prkc fusionsDarovasertib (IDE196)/ CrizotinibIdeaya BiosciencesOngoing
Jul 14, 2017A phase I/II, open-label, multi-center study of the safety and efficacy of IMCGP100 using the intra-patient escalation dosing regimen patients with advanced…IMCGP100ImmunocoreOngoing
Mar 30, 2017A phase II randomized, open-label, multi-center study of the safety and efficacy of IMCGP100 compared with investigator's choice in hla-a*0201 positive…IMCGP100ImmunocoreOngoing
Apr 9, 2014A phase Ib/II, open-label, multicenter study of AEB071 and MEK162 in adult patients with metastatic uveal melanomaMEK162/ AEB071/medronic acid/technetium tc 99MNovartis PharmaceuticalsPending
Jan 16, 2014A randomised, double-blind study to assess the efficacy of selumetinib (AZD6244, hyd-sulfate) in combination with dacarbazine compared with placebo in…SelumetinibAstraZeneca PharmaceuticalsClosed

FDA orphan designations

Approved first, then open designations, newest first
Aug 14, 2023HepzatoAs a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the…Delcath Systems, Inc.Approved
Jan 25, 2022KimmtrakTreatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanomaImmunocore LtdApproved
Nov 19, 2025Selective histone deacetylase 8 (HDAC8) inhibitorTreatment of uveal melanomaNovelwise Pharmaceuticals CorporationDesignated
Nov 1, 2025Anzutresgene autoleucelTreatment of uveal melanomaImmaticsDesignated
Sep 17, 2024Aptamer-drug conjugate (ApDC) comprising a c-Met aptamer…Treatment of uveal melanomaHangzhou Institute of Medicine, Chinese Academy of SciencesDesignated
Nov 1, 2022[6-Fluoro-1-(4-morpholin-4-ylmethyl-phenyl)-5,5-dioxo-4,5-di…Treatment of uveal melanomaiOnctura SADesignated
Apr 27, 2022DarovasertibTreatment of Uveal MelanomaIDEAYA Biosciences Inc.Designated
Feb 15, 2022SalinomycinTreatment of uveal melanomaHillstream Biopharma, Inc.Designated
Feb 19, 20211-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-t…Treatment of uveal melanomaLinnaeus Therapeutics, Inc.Designated
Feb 28, 2019Ac-225-4-PHenylbutyryl-His-D-Phe-Arg-Trp-Gly-Lys(eAhx-DOTA)-…Treatment of Uveal MelanomaModulation Therapeutics IncorporatedDesignated
Apr 8, 2015Modified human papillomavirus capsid protein conjugated to…Treatment of uveal melanomaAura Biosciences, Inc.Designated
Jun 24, 2008Vincristine sulfate liposomesTreatment of metastatic uveal melanoma.Acrotech Biopharma LLCDesignated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Apr 1, 2022KimmtrakTebentafusp · orphanImmunocore Ireland LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.